Johnson & Johnson (J&J) has unveiled new information about the future of AI in healthcare, announcing that AI will help cut drug development leads’ identification process by up to 50%.
Accelerated by AI, Lead Optimization
Executives from the J&J group of companies report that the process of generating drug development leads will soon be significantly accelerated thanks to AI. Typically, this step—known as lead optimization—used to require years of effort, yet the company expects AI will help make it twice as fast.
Instead of using trial-and-error approaches or manual search of potentially effective drug components, AI-driven platforms analyze huge data sets to select optimal chemical compounds or biologics. In other words, the use of AI enables more rapid drug candidate identification. Learn more about AI in drug discovery.
Screening Versus Optimization
As J&J claims, AI will help the company conduct faster and more effective screening of the universe of potential drug compounds. Although today AI does not design whole drugs, it contributes greatly to their optimization and early stages of creation.
This change is significant for the pharmaceutical sector since traditionally it was rather difficult to develop effective medicines due to high expenses and long periods required for drug discovery. Explore insights on pharmaceutical R&D.
How AI Will Revolutionize Health Care Industry
Typically, it takes about ten years and several billion dollars to bring one drug to market. However, through enhanced efficiency at each phase of work, the application of AI might help cut the time significantly.
Specifically, consistent reduction of time spent on early optimization might result in:
- Earlier delivery of potentially lifesaving medicines
- Savings in research and development expenses
- Improved treatment of challenging diseases through innovative solutions
Discover more about AI in healthcare innovation.
Role of AI in Pharmaceutical Industry
Notably, J&J is far from being the only company applying AI in the field of medicine. For example, there is also Roche which recently partnered with NVIDIA to implement AI into drug development practices.
Currently, companies such as J&J use artificial intelligence to:
- Discover novel drug targets
- Optimize drug candidates during lead optimization
- Conduct better and more efficient clinical trials
- Make changes in production methods
Learn more about clinical trials and AI.
Conclusion
The above-mentioned example shows that nowadays AI has already become an indispensable part of pharmaceutical innovations, although full automation of drug development might be realized later on.
For more Breaking AI news visit: https://breakingai.news
